Drugs and Therapy Bulletin

Drugs & Therapy Bulletin is a monthly publication by the Department of Pharmacy Services and the Pharmacy and Therapeutics Committee of Shands at the University of Florida. Each month, this newsletter highlights the most important drug topics that challenge our department.

The contents of our most recent volumes are listed below. Please click on the desired issue to view the .pdf document. For older issues, please visit our archive page.

2013 Volume 27

May, Number 5

  • Formulary Update
  • The Route Less Traveled
  • High-priority, Restricted-distribution drugs

April, Number 4

  • Formulary Update
  • Formulary Categories
  • A New Online Formulary
  • Nursing’s Medication and Administration Policy

March, Number 3

  • Formulary Update
  • Why isn’t hydrocodone listed in the Formulary?
  • Alternatives when an NSAID fails?

February, Number 2

  • Formulary Update
  • Drug Dosing in Renal Impairment
  • New Drugs in 2012

January, Number 1

  • Formulary Update
  • Why we still use animal products
  • New C. difficile treatment algorithm endorsed

2012 Volume 26

November/December, Number 10

  • Formulary Update
  • Delete codeine from the Formulary?
  • Compounding pharmacies and fungal meningitis
  • 2012 Annual index

October, Number 9

  • Formulary Update
  • Oral Contraceptives and Thromboembolic Risk
  • Medication Safety Subcommittee
  • CYP2C19 Reporting Changes

August/September, Number 8

  • Formulary Update
  • Can dabigatran CAUSE clots?

July, Number 7

  • Formulary Update
  • Medicaid restricts oxycodone prescribing for children
  • Should the inpatient use of TNF-alpha drugs be restricted?

June, Number 6

  • Formulary Update
  • Don’t get burned: Use sunscreen appropriately

May, Number 5

  • Formulary Update
  • Updated pharmacokinetic consult policy
  • Mandatory Oral Hypotensive Administration Instructions
  • Anticoagulation Management at Shands at UF

April, Number 4

  • Formulary Update
  • Update on Drug Shortages
  • Is the PDR Obsolete?

March, Number 3

  • Formulary Update
  • Opioid Prescribing in “Naive” or “Tolerant” Patients
  • Using Epic to Document Criteria for Use
  • What’s all the hype…about hyperglycemia?

February, Number 2

  • Formulary Update
  • New Drugs in 2011
  • Pardon My Language: What is PML?
  • New Personalized Medicine Subcommittee

January, Number 1

  • Formulary Update
  • Three Routes of Acetaminophen:
    Three Ways to Achieve the Same Result
  • Cardiovascular Drug-Induced DM

2011 – Volume 25

November/December 2011, Number 10 (pdf)

  • Formulary Update
  • The Formulary and the P&T Committee
  • 2011 Annual Index

October 2011, Number 9 (pdf)

  • Formulary Update
  • Restrict IV acetylcysteine use for the prevention of radiocontrast- induced nephropathy
  • Bisphosphonates and atypical femur fractures: A bone of contention

September 2011, Number 8 (pdf)

  • Formulary Update
  • New Florida law for controlled substances

July 2011, Number 7 (pdf)

  • Formulary Update
  • If to err is human, is CPOE divine?
  • P&T committee-approved authorized changes to med lists
  • Hey! Stop buggin’ me! General characteristics of insect repellants

June 2011, Number 6 (pdf)

  • Formulary Update
  • The truth about drug fever

May 2011, Number 5 (pdf)

  • Formulary Update
  • Prescription drug trends 2010

April 2011, Number 4 (pdf)

  • Formulary Update
  • What’s so special about specialty pharmacies?
  • SALAS: Arista® versus Arixtra®

March 2011, Number 3 (pdf)

  • Formulary Update
  • Proposal: Delete IV Phenergan® from the Formulary

February 2011, Number 2 (pdf)

  • Formulary Update
  • Abandoned prescriptions?
  • New drugs in 2011

January 2011, Number 1 (pdf)

  • Formulary Update
  • DTaP and Tdap: Understanding the letters
  • Is erythromycin preferred to azithromycin as a prokinetic?
  • Editorial: Twenty-five years of Bulletin

Archive

Visit Archive for Previous Issues